HOME >> MEDICINE >> NEWS
Anti-coagulation drugs found to have different effects in diabetics after heart attack

CHICAGO -- In a sub-analysis of data from an earlier trial comparing the ability of three agents used to restore blood flow to patients soon after heart attacks, researchers have found that drugs used to prevent blood coagulation appear to have different effects in heart patients with diabetes.

These findings, coupled with an assessment of ease of administration and cost compared to other drugs, leads researchers from Duke University Medical Center to recommend the drug enoxaparin, which is a low-molecular weight heparin, for acute heart attack patients with diabetes.

The Duke team reported the results of its analysis today (Nov. 20, 2002) at the 75th annual scientific session of the American Heart Association.

When heart attack patients are rushed to the emergency room, physicians immediately try to restore blood flow to the heart, usually by giving medications that dissolve clots in the coronary arteries. Since no one drug has been totally effective on its own in opening clogged arteries and keeping them open, researchers have tried different combinations of agents.

Thus was born the ASSENT-3 trial, the results of which were published in August 2001 in the journal Lancet. The trial enrolled 6,116 patients and documented the combined rates of death, recurrent heart attack or refractory chest pain. They then used this composite endpoint to measure the effectiveness of three different combinations of drugs.

All patients entered the hospital within six hours of a heart attack and were given varying doses of tenecteplase, a genetically altered version of the well-known clot-buster t-PA, which quickly dissolves the blood clot. Patients were then randomized to receive additional agents intended to keep the vessels clear: the blood-thinner enoxaparin; the blood-thinner unfractionated heparin plus abciximab (an agent that keeps platelets in the blood from clumping); or unfractionated heparin alone.

ASSENT-3 found that both th
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
20-Nov-2002


Page: 1 2 3

Related medicine news :

1. UW research shows risk factors for relapse among health care professionals who abuse drugs
2. New studies show mixed results on epilepsy drugs and birth defects
3. Newly discovered pathway might help in design of cancer drugs
4. Study examines consequences of Thailands war on drugs
5. Computational tool predicts how drugs work in cells, advancing efforts to design better medicines
6. Three anti-platelet drugs used in combination are safe
7. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
8. Clot-busting drugs may help detect potentially deadly leg clots
9. Herb used to treat diabetes works like modern-day prescription drugs, study suggests
10. Penn study shows how next-generation diabetic drugs could work more selectively
11. Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

Post Your Comments:
(Date:3/6/2015)... Follow us on LinkedIn – ... drug refers to testing of absorption, distribution, metabolism, and ... toxicity studies are clubbed together with ADME, it is ... on lowering costs and time during drug development are ... drug development model uses toxicity and efficacy testing in ...
(Date:3/6/2015)... USA (PRWEB) March 06, 2015 Parents ... the fatal reality of substance use disorders. School programs ... to be marginally successful. NOPE, or Narcotics Overdose Prevention ... nationwide, according to Healthline News on Feb. ... illicit and prescription opiate drugs, drug prevention proponents are ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... DC (PRWEB) March 06, 2015 Magellan ... nation’s only comprehensive source for key trends and statistics ... spend, medical injectables. Executives from Magellan Rx Management will ... Trend Report: Discover Your Hidden Specialty Drug Spend,” a ... Information Services, Inc. , Specialty drug spend makes up ...
(Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
(Date:3/6/2015)... WILMINGTON, Del. , March 6, 2015 /PRNewswire/ ... Patent and Trademark Office,s publication of U.S. Patent ... Eating Disorder."  The ,249 Patent Application features claimed methods ... may be used to treat Binge Eating Disorder ... "information material," or "flyer or an advertisement," as ...
(Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
(Date:3/5/2015)... 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ) ... ended January 3, 2015.  , Revenues were $11.8 ... the Company and up 11% from $10.6 million in the ... a record, up 12% from $38.3 million in 2013. ... up from 48.6% in the fourth quarter of the prior ...
Breaking Medicine Technology:Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8
Cached News: